STL Index for: Alim R. Devani
OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data
The OX40-OX40 ligand pathway has emerged as a promising therapeutic target for moderate-to-severe atopic dermatitis, offering a novel approach that simultaneously addresses multiple inflammatory pathways involved in disease pathogenesis. This review examines phase II clinical trial data for three monoclonal antibodies targeting this pathway: amlitelimab, rocatinlimab, and telazorlimab.
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Explore the groundbreaking role of Spesolimab, a novel interleukin-36 inhibitor, in treating Generalized Pustular Psoriasis flares in adults. This article presents key findings from phase 1 and 2 clinical trials, emphasizing Spesolimab's effectiveness and safety.
Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.
